Cargando…
Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides
PURPOSE: Fibroblast activation protein-α (FAP)-targeting radioligands have recently demonstrated high diagnostic potential. However, their therapeutic value is impaired by the short tumor residence time. Several strategies have been tested to overcome this limitation, but a head-to-head comparison h...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382406/ https://www.ncbi.nlm.nih.gov/pubmed/37261473 http://dx.doi.org/10.1007/s00259-023-06272-7 |
_version_ | 1785080672299253760 |
---|---|
author | Millul, Jacopo Koepke, Lennart Haridas, Gaonkar Raghuvir Sparrer, Konstantin M. J. Mansi, Rosalba Fani, Melpomeni |
author_facet | Millul, Jacopo Koepke, Lennart Haridas, Gaonkar Raghuvir Sparrer, Konstantin M. J. Mansi, Rosalba Fani, Melpomeni |
author_sort | Millul, Jacopo |
collection | PubMed |
description | PURPOSE: Fibroblast activation protein-α (FAP)-targeting radioligands have recently demonstrated high diagnostic potential. However, their therapeutic value is impaired by the short tumor residence time. Several strategies have been tested to overcome this limitation, but a head-to-head comparison has never been done. With the aim to identify strengths and limitations of the suggested strategies, we compared the monomer FAPI-46 versus (a) its dimer (FAPI-46-F1D), (b) two albumin binders conjugates (FAPI-46-Ibu (ibuprofen) and FAPI-46-EB (Evans Blue)), and (c) cyclic peptide FAP-2286. METHODS: (177)Lu-labeled ligands were evaluated in vitro in cell lines with low (HT-1080.hFAP) and high (HEK-293.hFAP) humanFAP expression. SPECT/CT imaging and biodistribution studies were conducted in HT-1080.hFAP and HEK-293.hFAP xenografts. The areas under the curve (AUC) of the tumor uptake and tumor-to-critical-organs ratios and the absorbed doses were estimated. RESULTS: Radioligands showed IC(50) in the picomolar range. Striking differences were observed in vivo regarding tumor uptake, residence, specificity, and total body distribution. All [(177)Lu]Lu-FAPI-46-based radioligands showed similar uptake between the two tumor models. [(177)Lu]Lu-FAP-2286 showed higher uptake in HEK-293.hFAP and the least background. The AUC of the tumor uptake and absorbed dose was higher for [(177)Lu]Lu-FAPI-46-F1D and the two albumin binder conjugates, [(177)Lu]Lu-FAPI-46-Ibu and [(177)Lu]Lu-FAPI-46-EB, in HT1080.hFAP xenografts and for [(177)Lu]Lu-FAPI-46-EB and [(177)Lu]Lu-FAP-2286 in HEK293.hFAP xenografts. The tumor-to-critical-organs AUC values and the absorbed doses were in favor of [(177)Lu]Lu-FAP-2286, but tumor-to-kidneys. CONCLUSION: The study indicated dimerization and cyclic peptide structures as promising strategies for prolonging tumor residence time, sparing healthy tissues. Albumin binding strategy outcome depended on the albumin binding moiety. The peptide showed advantages in terms of tumor-to-background ratios, besides tumor-to-kidneys, but its tumor uptake was FAP expression–dependent. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-023-06272-7. |
format | Online Article Text |
id | pubmed-10382406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-103824062023-07-30 Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides Millul, Jacopo Koepke, Lennart Haridas, Gaonkar Raghuvir Sparrer, Konstantin M. J. Mansi, Rosalba Fani, Melpomeni Eur J Nucl Med Mol Imaging Original Article PURPOSE: Fibroblast activation protein-α (FAP)-targeting radioligands have recently demonstrated high diagnostic potential. However, their therapeutic value is impaired by the short tumor residence time. Several strategies have been tested to overcome this limitation, but a head-to-head comparison has never been done. With the aim to identify strengths and limitations of the suggested strategies, we compared the monomer FAPI-46 versus (a) its dimer (FAPI-46-F1D), (b) two albumin binders conjugates (FAPI-46-Ibu (ibuprofen) and FAPI-46-EB (Evans Blue)), and (c) cyclic peptide FAP-2286. METHODS: (177)Lu-labeled ligands were evaluated in vitro in cell lines with low (HT-1080.hFAP) and high (HEK-293.hFAP) humanFAP expression. SPECT/CT imaging and biodistribution studies were conducted in HT-1080.hFAP and HEK-293.hFAP xenografts. The areas under the curve (AUC) of the tumor uptake and tumor-to-critical-organs ratios and the absorbed doses were estimated. RESULTS: Radioligands showed IC(50) in the picomolar range. Striking differences were observed in vivo regarding tumor uptake, residence, specificity, and total body distribution. All [(177)Lu]Lu-FAPI-46-based radioligands showed similar uptake between the two tumor models. [(177)Lu]Lu-FAP-2286 showed higher uptake in HEK-293.hFAP and the least background. The AUC of the tumor uptake and absorbed dose was higher for [(177)Lu]Lu-FAPI-46-F1D and the two albumin binder conjugates, [(177)Lu]Lu-FAPI-46-Ibu and [(177)Lu]Lu-FAPI-46-EB, in HT1080.hFAP xenografts and for [(177)Lu]Lu-FAPI-46-EB and [(177)Lu]Lu-FAP-2286 in HEK293.hFAP xenografts. The tumor-to-critical-organs AUC values and the absorbed doses were in favor of [(177)Lu]Lu-FAP-2286, but tumor-to-kidneys. CONCLUSION: The study indicated dimerization and cyclic peptide structures as promising strategies for prolonging tumor residence time, sparing healthy tissues. Albumin binding strategy outcome depended on the albumin binding moiety. The peptide showed advantages in terms of tumor-to-background ratios, besides tumor-to-kidneys, but its tumor uptake was FAP expression–dependent. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-023-06272-7. Springer Berlin Heidelberg 2023-06-01 2023 /pmc/articles/PMC10382406/ /pubmed/37261473 http://dx.doi.org/10.1007/s00259-023-06272-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Millul, Jacopo Koepke, Lennart Haridas, Gaonkar Raghuvir Sparrer, Konstantin M. J. Mansi, Rosalba Fani, Melpomeni Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides |
title | Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides |
title_full | Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides |
title_fullStr | Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides |
title_full_unstemmed | Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides |
title_short | Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides |
title_sort | head-to-head comparison of different classes of fap radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382406/ https://www.ncbi.nlm.nih.gov/pubmed/37261473 http://dx.doi.org/10.1007/s00259-023-06272-7 |
work_keys_str_mv | AT milluljacopo headtoheadcomparisonofdifferentclassesoffapradioligandsdesignedtoincreasetumorresidencetimemonomerdimeralbuminbindersandsmallmoleculesvspeptides AT koepkelennart headtoheadcomparisonofdifferentclassesoffapradioligandsdesignedtoincreasetumorresidencetimemonomerdimeralbuminbindersandsmallmoleculesvspeptides AT haridasgaonkarraghuvir headtoheadcomparisonofdifferentclassesoffapradioligandsdesignedtoincreasetumorresidencetimemonomerdimeralbuminbindersandsmallmoleculesvspeptides AT sparrerkonstantinmj headtoheadcomparisonofdifferentclassesoffapradioligandsdesignedtoincreasetumorresidencetimemonomerdimeralbuminbindersandsmallmoleculesvspeptides AT mansirosalba headtoheadcomparisonofdifferentclassesoffapradioligandsdesignedtoincreasetumorresidencetimemonomerdimeralbuminbindersandsmallmoleculesvspeptides AT fanimelpomeni headtoheadcomparisonofdifferentclassesoffapradioligandsdesignedtoincreasetumorresidencetimemonomerdimeralbuminbindersandsmallmoleculesvspeptides |